News

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...
We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ ...
Findings showed mNexspike showed a 9.3% (99.4% CI, -6.6, 22.8) higher relative vaccine efficacy compared with Moderna’s original COVID-19 vaccine.
"The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," said Stéphane Bancel, CEO of Moderna. "COVID-19 ...
Moderna's new vaccine (mNexspike [COVID-19 Vaccine, mRNA]) represents a significant step forward in the development of next-generation coronavirus vaccines, the Associated Press reported.
This is the same limited use the FDA set in licensing the Novavax COVID-19 vaccine last month. This fall, Moderna anticipates offering both Spikevax and mNexspike as COVID-19 vaccines.
Per Moderna, mNexspike offers improved shelf life and storage benefits — key advantages for broad U.S. distribution, especially in areas with limited cold-chain infrastructure.
Moderna had originally sought broader approval for use in individuals aged 12 and older, regardless of health status. mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original ...